Clonal Hematopoiesis in Patients With Human Immunodeficiency Virus and Cancer.

Autor:	Gillis N; Department of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.; Department of Malignant Hematology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Dickey BL; Department of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.; Center for Immunization and Infection Research in Cancer, Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Colin-Leitzinger C; Department of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Tang YH; Department of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Putney RM; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Mesa TE; Molecular Genomics Core Facility, Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Yoder SJ; Molecular Genomics Core Facility, Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Suneja G; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.; Department of Radiation Oncology, Salt Lake City, UT, USA., Spivak AM; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.; Division of Infectious Diseases, Department of Medicine, University of Utah, Salt Lake City, UT, USA., Patel AB; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.; Division of Hematology and Hematologic Malignancies, Department of Medicine, University of Utah, Salt Lake City, UT, USA., Extermann M; Senior Adult Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Giuliano AR; Department of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.; Center for Immunization and Infection Research in Cancer, Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Teng M; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Kresovich J; Department of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.; Department of Breast Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Berglund A; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Coghill AE; Department of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.; Center for Immunization and Infection Research in Cancer, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.; Department of Gastrointestinal Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Jazyk:	angličtina
Zdroj:	The Journal of infectious diseases [J Infect Dis] 2024 Sep 23; Vol. 230 (3), pp. 680-688.
DOI:	10.1093/infdis/jiae212
Abstrakt:	Background: Cancer-related deaths for people with human immunodeficiency virus (PWH) are increasing due to longer life expectancies and disparately poor cancer-related outcomes. We hypothesize that advanced biological aging contributes to cancer-related morbidity and mortality for PWH and cancer. We sought to determine the impact of clonal hematopoiesis (CH) on cancer disparities in PWH. Methods: We conducted a retrospective study to compare the prevalence and clinical outcomes of CH in PWH and people without HIV (PWoH) and cancer. Included in the study were PWH and similar PWoH based on tumor site, age, tumor sequence, and cancer treatment status. Biological aging was also measured using epigenetic methylation clocks. Results: In 136 patients with cancer, PWH had twice the prevalence of CH compared to similar PWoH (23% vs 11%, P = .07). After adjusting for patient characteristics, PWH were 4 times more likely than PWoH to have CH (odds ratio, 4.1 [95% confidence interval, 1.3-13.9]; P = .02). The effect of CH on survival was most pronounced in PWH, who had a 5-year survival rate of 38% if they had CH (vs 59% if no CH), compared to PWoH who had a 5-year survival rate of 75% if they had CH (vs 83% if no CH). Conclusions: This study provides the first evidence that PWH may have a higher prevalence of CH than PWoH with the same cancers. CH may be an independent biological aging risk factor contributing to inferior survival for PWH and cancer. Competing Interests: Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu